Wednesday, January 9, 2013
Bristol-Myers Squibb Symposium
Pharmaceutical Process Chemistry at Bristol-Myers Squibb and the Preparation of Brivanib Alaninate
Jaan Pesti, Dr., Early Phase Research & Development, Bristol-Myers Squibb
An introduction to the practice of process chemistry with further insights to its manifestation in pharmaceutical chemistry at BMS. The process development of a potential oncology drug, brivanib alaninate, will be described.